contrave
July 21st, 2009
By Deena Beasley LOS ANGELES, July 20 – Orexigen Therapeutics Inc said on Monday that three late-stage trials of its Contrave experimental weight-loss drug had met their goals, sending its shares up nearly 25 percent . Contrave, an experimental weight loss drug that combines the antidepressant Wellbutrin with the addiction drug naltrexone, looks effective in late-stage studies. SAN DIEGO July 17 /- Orexigen(R) Therapeutics ,Orexigen(R),Therapeutics,Schedules,July,20,,2009,Teleconference,and,Webcast,Discussion,of,Contrave(R),Phase,3,Results,medicine,advanced medical technology,medical laboratory